Jeff Jones
Stock Analyst at Oppenheimer
(0.68)
# 3,776
Out of 4,759 analysts
85
Total ratings
16.44%
Success rate
-17.17%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Initiates: Outperform | $32 | $5.21 | +514.20% | 1 | Jan 30, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $10.02 | +79.64% | 4 | Jan 24, 2025 | |
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.29 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $3.02 | +429.80% | 7 | Nov 22, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $6.24 | +268.59% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.96 | +461.22% | 7 | Nov 15, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $8 → $14 | $4.88 | +186.89% | 3 | Nov 13, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $1.71 | +426.32% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $36.88 | +51.84% | 4 | Sep 27, 2024 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $35 → $39 | $26.60 | +46.62% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $87 → $89 | $29.60 | +200.68% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $3.04 | +1,380.26% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $8.51 | +934.08% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.83 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $21 | $1.55 | +1,254.84% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.12 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $30 | $31.03 | -3.32% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.37 | +32,184.10% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.96 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.39 | +979.14% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $2.18 | +3,340.37% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.49 | +44,076.71% | 2 | Nov 17, 2022 |
Alumis
Jan 30, 2025
Initiates: Outperform
Price Target: $32
Current: $5.21
Upside: +514.20%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $10.02
Upside: +79.64%
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.29
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.02
Upside: +429.80%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $6.24
Upside: +268.59%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.96
Upside: +461.22%
Corvus Pharmaceuticals
Nov 13, 2024
Reiterates: Outperform
Price Target: $8 → $14
Current: $4.88
Upside: +186.89%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $1.71
Upside: +426.32%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $36.88
Upside: +51.84%
ArriVent BioPharma
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $26.60
Upside: +46.62%
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $29.60
Upside: +200.68%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $3.04
Upside: +1,380.26%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $8.51
Upside: +934.08%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.83
Upside: -
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $1.55
Upside: +1,254.84%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.12
Upside: -
Feb 29, 2024
Maintains: Neutral
Price Target: $32 → $30
Current: $31.03
Upside: -3.32%
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.37
Upside: +32,184.10%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.96
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.39
Upside: +979.14%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $2.18
Upside: +3,340.37%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.49
Upside: +44,076.71%